for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Orphazyme A/S

ORPHA.CO

Latest Trade

32.80DKK

Change

3.70(+12.71%)

Volume

88,155

Today's Range

29.02

 - 

32.80

52 Week Range

22.02

 - 

109.10

As of on the Copenhagen Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
29.10
Open
29.08
Volume
88,155
3M AVG Volume
16.77
Today's High
32.80
Today's Low
29.02
52 Week High
109.10
52 Week Low
22.02
Shares Out (MIL)
34.95
Market Cap (MIL)
1,027.60
Forward P/E
-1.61
Dividend (Yield %)
--

Next Event

Orphazyme A/S Annual Shareholders Meeting

Latest Developments

More

Orphazyme H1 Net Loss At DKK 463.8.0 Mln

Orphazyme Publishes Positive Results From Phase 2 Trial Of Arimoclomol

Orphazyme Announces Restructuring To Focus Resources On Supporting A Path Forward For Arimoclomol In NPC

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Orphazyme A/S

Orphazyme A/S, formerly Orphazyme ApS, is a Denmark-based company active within the biopharmaceutical industry. It develops new therapies for the treatment of a family of genetic disorders. The Company's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company’s candidate, arimoclomol, stimulates the production of the cells’ protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells’ recycling system, the lysosomes, so they no longer form toxic aggregates. The Company collaborates with academic institutions in Europe and the United States.

Industry

Biotechnology & Drugs

Contact Info

Ole Maaloees Vej 3, Copenhagen N

2200

Denmark

https://www.orphazyme.com/

Executive Leadership

Georges Gemayel

Chairman of the Board

Christophe Bourdon

Chief Executive Officer

Bo Jesper Hansen

Deputy Chairman of the Board

Anders Fink Vadsholt

Chief Financial Officer

Thomas Kirkegaard Jensen

Chief Scientific Officer

Key Stats

5.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, DKK)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (DKK)

2018

-11.500

2019

-16.870

2020

-22.320

2021(E)

-18.240
Price To Earnings (TTM)
--
Price To Sales (TTM)
78.13
Price To Book (MRQ)
6.16
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
35.13
LT Debt To Equity (MRQ)
13.55
Return on Investment (TTM)
-222.84
Return on Equity (TTM)
-153.14

Latest News

Latest News

Danish 'meme stock' Orphazyme plunges after drug setback

Orphazyme slashed its financial forecasts on Friday after U.S. health regulators rejected its key drug candidate, sending shares in Denmark's first so-called meme stock tumbling 75% in early trading.

BRIEF-Orphazyme Updates On Phase 2 Study Of Arimoclomol In Gaucher Disease

* ORPHAZYME A/S - PHASE 2 STUDY OF ARIMOCLOMOL IN GAUCHER DISEASE DEMONSTRATES MARKED IMPROVEMENTS IN KEY CLINICAL MARKERS

BRIEF-Orphazyme Says Novo Holdings Holds Less Than 5% Of Total Share Capital And Total Voting Rights Of Co

* NOVO HOLDINGS AS OF TODAY HOLDS SHARES CORRESPONDING TO LESS THAN 5% OF TOTAL SHARE CAPITAL AND TOTAL VOTING RIGHTS OF CO Source text for Eikon: Further company coverage:

BRIEF-Orphazyme Initiates Rolling Submission Of New Drug Application For Arimoclomol

* REG-ORPHAZYME INITIATES ROLLING SUBMISSION OF NEW DRUG APPLICATION FOR ARIMOCLOMOL WITH US FDA IN NIEMANN-PICK DISEASE TYPE C

BRIEF-Orphazyme: FDA Fast Track Designation For Arimoclomol In Amyotrophic Lateral Sclerosis

* ORPHAZYME’S ARIMOCLOMOL RECEIVES US FAST TRACK DESIGNATION IN AMYOTROPHIC LATERAL SCLEROSIS

BRIEF-Orphazyme FY Net Loss Widens To DKK 337.5 Mln

* FY NET LOSS DKK 337.5 MILLION VERSUS LOSS DKK 229.6 MILLION YEAR AGO

BRIEF-Orphazyme Completes Offering Of 7,032,937 Shares In Directed Issue And Private Placement

* REG-ORPHAZYME COMPLETES OFFERING OF 7,032,937 SHARES IN A DIRECTED ISSUE AND PRIVATE PLACEMENT AND RAISES APPROXIMATELY DKK 745,000,000 (EUR 100 MILLION/USD 110 MILLION)

BRIEF-Orphazyme Says Board Resolved To Initiate Directed Issue And Private Placement Of Shares

* ORPHAZYME - BOARD RESOLVED TO INITIATE DIRECTED ISSUE AND PRIVATE PLACEMENT OF UP TO AGGREGATE OF 7,032,937 NEW SHARES, EXISTING SHARES Source text for Eikon: Further company coverage:

BRIEF-Orphazyme Prepares To File Acrimoclomol In Europe For Niemann-Pick Disease Type C

* CONFIRMS ITS INTENTION TO FILE THE MARKETING AUTHORIZATION APPLICATION FOR NIEMANN-PICK DISEASE TYPE C IN H1 2020

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up